HACKENSACK, N.J., March 30 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. will present Friday, April 1, at 9:00 AM Eastern during the Lehman Brothers Eighth Annual Global Healthcare Conference in Miami, Florida at the Loews Miami Beach Hotel. Barbara Duncan, DOV’s Chief Financial Officer, will discuss recent business developments and highlight the company’s clinical development plan.
The audio portion of the corporate presentation may be accessed through the following link: http://customer.talkpoint.com/LEHM002/033005a_cs/default.asp?entity=DOV. In addition, the slide presentation may be accessed through a link in the investor relations section of DOV’s website: http://www.dovpharm.com/. Presentations will be archived and available after the conference for a period of 90 days.
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system and other disorders, including cardiovascular, that involve alterations in neuronal processing. The Company has six product candidates undergoing clinical development that address therapeutic indications with significant unmet needs. In addition, its partner, Neurocrine, in the fourth quarter of 2004 filed two NDAs, the first for an immediate release formulation and the second for a modified release formulation of indiplon for the treatment of insomnia. However, Neurocrine has reported that these applications were not accepted by the FDA due to technical difficulties in navigating the electronic filings and that it intends to refile the applications in the first half of 2005.
DOV Pharmaceutical, Inc.
CONTACT: Barbara Duncan, Chief Financial Officer of DOV Pharmaceutical,Inc., +1-201-968-0980; or Corporate Communications, Kathleen Eppolito ofScientia Communications, Inc., +1-718-281-1809
Web site: http://www.dovpharm.com/
